\n
Having spent the previous decade constructing its place in neurology and immunology, Belgian biopharma UCB\u2019s pipeline technique is now targeted on turning these core areas into the following technology of progress. Moderately than branching out into solely new therapeutic areas, the corporate is trying to newer modalities and doubtlessly disease-modifying approaches to additional\u00a0preserve\u00a0its place inside these two sectors.\u00a0<\/p>\n
UCB\u2019s current dealmaking supplies a transparent illustration of this technique. Up to now yr, the corporate has\u00a0acquired\u00a0cell remedy developer\u00a0Neurona Therapeutics\u00a0and\u00a0T-cell engager specialist\u00a0Candid Therapeutics, whereas additionally\u00a0placing\u00a0a worldwide licensing settlement with Antengene for one more B-cell-depleting bispecific antibody. Collectively, the offers have introduced novel approaches spanning regenerative medication,\u00a0T-cell engagement, and immune modulation into UCB\u2019s pipeline.\u00a0<\/p>\n
Moreover, with blockbuster drug\u00a0Bimzelx\u00a0persevering with to drive progress in immunology and a longtime neurology portfolio, the corporate already has a powerful business basis. However can its technique of concentrating on these core therapeutic areas whereas utilizing dealmaking to speed up entry to modern applied sciences ship the following decade of progress? On this article, we take a better have a look at UCB\u2019s pipeline technique and the offers serving to to form its future.\u00a0<\/p>\n
UCB\u2019s immunology pipeline: Constructing the following technology of autoimmune therapies\u00a0<\/h2>\n
Immunology has develop into one of the vital necessary pillars of UCB\u2019s progress technique, with the corporate more and more trying past standard approaches to treating continual inflammatory ailments.\u00a0\u00a0<\/p>\n
Its established portfolio already supplies\u00a0a powerful basis, led by\u00a0Bimzelx\u00a0(bimekizumab), which targets IL-17A and IL-17F and has develop into UCB\u2019s key progress driver after receiving 5 approvals in simply two years for numerous autoimmune indications. First getting into the market as a plaque psoriasis treatment, it has since been authorised for energetic psoriatic arthritis, energetic non-radiographic axial spondyloarthritis, energetic ankylosing spondylitis and, most not too long ago, hidradenitis suppurativa (HS). After its\u00a0preliminary\u00a0approval,\u00a0Bimzelx\u00a0gross sales ultimately skyrocketed, going from a modest \u20ac607 million ($716 million) in 2024 to\u00a0\u20ac2.22 billion\u00a0($2.6 billion) in 2025 \u2013 already midway to the corporate\u2019s\u00a0acknowledged\u00a0peak gross sales expectations of at the least \u20ac4 billion ($4.4 billion).\u00a0\u00a0<\/p>\n
Alongside increasing the\u00a0Bimzelx\u00a0franchise, UCB can also be pursuing therapies that would doubtlessly go additional than suppressing irritation and as a substitute deal with the underlying immune dysfunction driving autoimmune illness.\u00a0\u00a0<\/p>\n
One instance is\u00a0dapirolizumab\u00a0pegol, an anti-CD40 ligand antibody being developed with Biogen for systemic lupus erythematosus. Optimistic section 3 information not too long ago\u00a0revealed\u00a0within the Lancet confirmed that the drug plus normal of care\u00a0demonstrated\u00a0statistically important enchancment in illness exercise at week 48, strengthening the case for the drug as a possible new\u00a0choice\u00a0for sufferers with the complicated autoimmune illness. Moreover, UCB is advancing\u00a0galvokimig, a bispecific antibody focusing on IL-13 and IL-17A\/F, in atopic dermatitis and different inflammatory ailments, with section 2b topline ends in atopic dermatitis anticipated in 2028, in keeping with the corporate\u2019s web site.\u00a0\u00a0<\/p>\n
In the meantime, UCB\u2019s current dealmaking means that its ambitions in immunology prolong past merely including one other technology of anti-inflammatory medication. In March, the corporate\u00a0secured\u00a0worldwide rights to ATG-201 from Antengene, a CD19\/CD3 bispecific T-cell engager designed to selectively deplete B cells. And, simply two months later, it\u00a0introduced\u00a0the $2 billion upfront acquisition of Candid Therapeutics, including\u00a0cizutamig, a BCMA\/CD3 T-cell engager, to its pipeline. The acquisition was accomplished in June for as much as $2.2 billion and\u00a0introduced Candid\u2019s broader portfolio of multispecific T-cell engagers into UCB.\u00a0<\/p>\n
These two offers are significantly important as a result of they level in the direction of a typical technique. Moderately than focusing on inflammatory pathways alone, UCB is constructing capabilities across the selective depletion of pathogenic B-cell populations, with the\u00a0aim\u00a0of reaching what it calls an \u201cimmune reset.\u201d The thought is that eradicating the B cells answerable for producing disease-driving antibodies might doubtlessly ship deeper and extra sturdy illness management, and\u00a0even perhaps\u00a0intervals of treatment-free remission, in some autoimmune ailments.\u00a0\u00a0<\/p>\n
This platform-driven method might show significantly necessary as UCB seems to\u00a0set up\u00a0a brand new technology of immunology medicines. It doesn’t imply that it’s abandoning its current experience in monoclonal antibodies or its profitable inflammatory illness franchise by any means; as a substitute, it’s merely including new modalities that would enable it to sort out autoimmune ailments at a deeper organic stage and, within the course of, this additionally supplies it with a wider vary of medicines that would create long-term progress in a crowded immunology market.\u00a0\u00a0<\/p>\n
Neurology: From seizure management to disease-modifying therapies\u00a0<\/h2>\n
Neurology is the opposite main pillar of UCB\u2019s technique, and right here the corporate has an particularly\u00a0robust basis\u00a0to construct on. UCB has greater than 30 years of expertise in epilepsy, with established medicines together with\u00a0Fintepla\u00a0(fenfluramine),\u00a0Briviact\u00a0(brivaracetam), Vimpat (lacosamide), and Keppra (levetiracetam). Its present business portfolio spans each broad epilepsy therapies and therapies for uncommon epileptic syndromes equivalent to Dravet syndrome and Lennox-Gastaut\u00a0syndrome.\u00a0<\/p>\n
However whereas UCB continues to develop therapies geared toward enhancing seizure management, its pipeline more and more factors towards a extra bold aim: addressing the underlying biology of neurological ailments relatively than merely managing their signs. One instance is STACCATO alprazolam, an investigational drug-device mixture designed to quickly\u00a0terminate\u00a0extended seizures exterior of a hospital setting. The remedy is at the moment in section 3 of improvement with topline outcomes anticipated in This fall 2026\/H1 2027 and, if profitable, might supply sufferers and caregivers a brand new means of managing seizures at house.\u00a0<\/p>\n
UCB can also be trying past epilepsy. Considered one of its most necessary belongings right here is\u00a0rozanolixizumab, because it illustrates how the corporate is utilizing its\u00a0experience\u00a0in antibody-mediated illness to broaden its neurology franchise. The monoclonal antibody targets the neonatal Fc receptor (FcRn), decreasing the recycling of immunoglobulin G (IgG) antibodies, together with the pathogenic autoantibodies that drive sure neurological ailments.\u00a0\u00a0<\/p>\n
Already\u00a0authorised\u00a0in 2023 underneath the model title\u00a0Rystiggo\u00a0for adults with generalized myasthenia gravis, UCB is now exploring its potential in\u00a0further\u00a0indications, together with myelin oligodendrocyte glycoprotein antibody illness (MOGAD) and ocular myasthenia gravis. With the corporate anticipating topline outcomes from the section 3 MOGAD program within the second half of 2027,\u00a0rozanolixizumab\u00a0might present one other avenue for progress whereas demonstrating UCB\u2019s technique of increasing established medicines into new areas of neurological illness.\u00a0<\/p>\n
However it’s UCB\u2019s $1.15\u00a0billion\u00a0acquisition\u00a0of Neurona Therapeutics that\u00a0maybe greatest\u00a0illustrates how far the corporate desires to push its neurology technique. Accomplished in June 2026, the deal added\u00a0rezanecel\u00a0\u2013 beforehand often known as NRTX-1001 \u2013 a neuronal cell remedy that was being investigated by Neurona in section 1\/2 trials for drug-resistant mesial temporal lobe epilepsy. Moderately than merely suppressing irregular neuronal exercise, the remedy is designed to revive inhibitory interneuron perform, doubtlessly addressing a root reason behind seizures, and is run in a one-time, minimally invasive supply process.\u00a0\u00a0<\/p>\n
The acquisition, due to this fact,\u00a0represents\u00a0extra than simply one other addition to UCB\u2019s epilepsy portfolio; the Belgian biopharma explicitly described the deal as a \u201cstrategic enlargement\u201d into regenerative medication and superior therapies, with the corporate aiming to maneuver past symptomatic administration. If\u00a0rezanecel\u00a0can\u00a0exhibit\u00a0sturdy efficacy, it might doubtlessly supply\u00a0a really completely different\u00a0remedy paradigm from standard anti-seizure medicines, which\u00a0typically want\u00a0to be taken constantly to regulate signs. In keeping with its web site, UCB is planning to push the candidate into section 3 in H1 2027.\u00a0\u00a0<\/p>\n
Finally, UCB\u2019s\u00a0neurology technique mirrors its path in immunology: construct on a longtime business base whereas investing in applied sciences that would essentially change how critical ailments are handled. In immunology, which means shifting in the direction of deeper immune modulation and doubtlessly immune reset; in neurology, it means exploring whether or not the underlying nervous system could be\u00a0modified\u00a0or repaired.\u00a0\u00a0<\/p>\n
Can UCB\u2019s targeted pipeline technique ship long-term progress?\u00a0<\/h2>\n
For UCB, the outlook seems to be much less about discovering a wholly new progress engine and extra about guaranteeing that the 2 it already has can proceed to increase.\u00a0\u00a0<\/p>\n
The corporate entered 2026 with 5 core progress drivers:\u00a0Bimzelx,\u00a0Rystiggo,\u00a0Zilbrysq,\u00a0Fintepla, and\u00a0Evenity. In its fourth-quarter and full-year earnings\u00a0report\u00a0launched in February 2026, UCB stated that its web gross sales had been up by 32% in 2025 to \u20ac7.39 billion ($8.53 billion), pushed by the robust launch execution of those medicines. This provides UCB some respiration room because it invests within the subsequent technology of medicines.\u00a0\u00a0<\/p>\n
The corporate\u00a0expects\u00a0income to develop by a excessive single-digit to low double-digit share in 2026, regardless of the\u00a0anticipated\u00a0influence of\u00a0Briviact\u2019s\u00a0lack of exclusivity, with progress anticipated to be pushed primarily by its 5 core medicines. UCB has additionally stated that its present pipeline\u00a0incorporates\u00a0eight modern remedy choices, setting the stage for important milestones in 2026 and past.\u00a0<\/p>\n
However, in fact, the corporate shouldn’t be relying solely on its current portfolio to maintain that trajectory. The acquisitions of Neurona and Candid, alongside the Antengene partnership,\u00a0exhibit\u00a0a willingness to deploy important capital to speed up entry to applied sciences that would reshape its two core therapeutic areas. We might\u00a0anticipate\u00a0extra of this type of dealmaking within the second half of 2026 and into 2027.\u00a0\u00a0<\/p>\n
However, there are, as all the time, some dangers to be careful for. For instance, most of the applied sciences underpinning UCB\u2019s longer-term technique stay clinically unproven, and the corporate might want to\u00a0exhibit\u00a0that these bold approaches can translate into protected, efficient, and commercially\u00a0viable\u00a0medicines. On the identical time, it should proceed increasing its current merchandise rapidly sufficient to supply the income and money circulate wanted to fund this innovation.\u00a0\u00a0<\/p>\n
For now, although, UCB\u2019s pipeline technique seems to be delivering, and if its next-generation packages can replicate the business success of\u00a0Bimzelx\u00a0and its different progress drivers, UCB could have the components not simply to ship the following few years of progress, however to construct the longer-term pipeline wanted to maintain it for a decade and past.\u00a0<\/p>\n<\/div>\n
\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Having spent the previous decade constructing its place in neurology and immunology, Belgian biopharma UCB\u2019s pipeline technique is now targeted on turning these core areas into the following technology of progress. Moderately than branching out into solely new therapeutic areas, the corporate is trying to newer modalities and doubtlessly disease-modifying approaches to additional\u00a0preserve\u00a0its place inside […]<\/p>\n","protected":false},"author":1,"featured_media":3649,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/08\/UCB-pipeline.jpg","fifu_image_alt":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_override_bookmark_settings":[],"jnews_social_meta":[],"jnews_override_counter":[],"footnotes":""},"categories":[10],"tags":[3995,3438,3996,1139,28,3994],"class_list":["post-3647","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","tag-focusing","tag-immunology","tag-neurology","tag-pipeline","tag-strategy","tag-ucbs"],"yoast_head":"\n
UCB's pipeline technique: Specializing in immunology and neurology - Future News 24<\/title>\n<meta name=\"description\" content=\"Discover how UCB\u2019s pipeline strategy in 2026 is still focused on its core areas of immunology and neurology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UCB's pipeline technique: Specializing in immunology and neurology - Future News 24\" \/>\n<meta property=\"og:description\" content=\"Discover how UCB\u2019s pipeline strategy in 2026 is still focused on its core areas of immunology and neurology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/\" \/>\n<meta property=\"og:site_name\" content=\"Future News 24\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-12T13:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-12T18:59:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/08\/UCB-pipeline.jpg\" \/>\n<meta name=\"author\" content=\"Future News 24\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/08\/UCB-pipeline.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Future News 24\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/08\\\/12\\\/ucb-pipeline-strategy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/08\\\/12\\\/ucb-pipeline-strategy\\\/\"},\"author\":{\"name\":\"Future News 24\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\"},\"headline\":\"UCB’s pipeline technique: Specializing in immunology and neurology\",\"datePublished\":\"2026-08-12T13:00:00+00:00\",\"dateModified\":\"2026-08-12T18:59:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/08\\\/12\\\/ucb-pipeline-strategy\\\/\"},\"wordCount\":1669,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/08\\\/12\\\/ucb-pipeline-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/UCB-pipeline.jpg\",\"keywords\":[\"Focusing\",\"Immunology\",\"neurology\",\"pipeline\",\"Strategy\",\"UCBs\"],\"articleSection\":[\"BioTechnology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/08\\\/12\\\/ucb-pipeline-strategy\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/08\\\/12\\\/ucb-pipeline-strategy\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/08\\\/12\\\/ucb-pipeline-strategy\\\/\",\"name\":\"UCB's pipeline technique: Specializing in immunology and neurology - Future News 24\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/08\\\/12\\\/ucb-pipeline-strategy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/08\\\/12\\\/ucb-pipeline-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/UCB-pipeline.jpg\",\"datePublished\":\"2026-08-12T13:00:00+00:00\",\"dateModified\":\"2026-08-12T18:59:03+00:00\",\"description\":\"Discover how UCB\u2019s pipeline strategy in 2026 is still focused on its core areas of immunology and neurology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/08\\\/12\\\/ucb-pipeline-strategy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/08\\\/12\\\/ucb-pipeline-strategy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/08\\\/12\\\/ucb-pipeline-strategy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/UCB-pipeline.jpg\",\"contentUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/UCB-pipeline.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/08\\\/12\\\/ucb-pipeline-strategy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/futurenews24.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UCB’s pipeline technique: Specializing in immunology and neurology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"name\":\"Future News 24\",\"description\":\"The Smart Hub for AI and Next-Gen Innovation\",\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/futurenews24.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\",\"name\":\"Future News 24\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"contentUrl\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"width\":250,\"height\":250,\"caption\":\"Future News 24\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\",\"name\":\"Future News 24\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"caption\":\"Future News 24\"},\"sameAs\":[\"https:\\\/\\\/futurenews24.com\"],\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/author\\\/mridulpahuja20\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UCB's pipeline technique: Specializing in immunology and neurology - Future News 24","description":"Discover how UCB\u2019s pipeline strategy in 2026 is still focused on its core areas of immunology and neurology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/","og_locale":"en_US","og_type":"article","og_title":"UCB's pipeline technique: Specializing in immunology and neurology - Future News 24","og_description":"Discover how UCB\u2019s pipeline strategy in 2026 is still focused on its core areas of immunology and neurology.","og_url":"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/","og_site_name":"Future News 24","article_published_time":"2026-08-12T13:00:00+00:00","article_modified_time":"2026-08-12T18:59:03+00:00","og_image":[{"url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/08\/UCB-pipeline.jpg","type":"","width":"","height":""}],"author":"Future News 24","twitter_card":"summary_large_image","twitter_image":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/08\/UCB-pipeline.jpg","twitter_misc":{"Written by":"Future News 24","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/#article","isPartOf":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/"},"author":{"name":"Future News 24","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83"},"headline":"UCB’s pipeline technique: Specializing in immunology and neurology","datePublished":"2026-08-12T13:00:00+00:00","dateModified":"2026-08-12T18:59:03+00:00","mainEntityOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/"},"wordCount":1669,"commentCount":0,"publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/08\/UCB-pipeline.jpg","keywords":["Focusing","Immunology","neurology","pipeline","Strategy","UCBs"],"articleSection":["BioTechnology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/","url":"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/","name":"UCB's pipeline technique: Specializing in immunology and neurology - Future News 24","isPartOf":{"@id":"https:\/\/futurenews24.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/#primaryimage"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/08\/UCB-pipeline.jpg","datePublished":"2026-08-12T13:00:00+00:00","dateModified":"2026-08-12T18:59:03+00:00","description":"Discover how UCB\u2019s pipeline strategy in 2026 is still focused on its core areas of immunology and neurology.","breadcrumb":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/#primaryimage","url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/08\/UCB-pipeline.jpg","contentUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/08\/UCB-pipeline.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/futurenews24.com\/index.php\/2026\/08\/12\/ucb-pipeline-strategy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/futurenews24.com\/"},{"@type":"ListItem","position":2,"name":"UCB’s pipeline technique: Specializing in immunology and neurology"}]},{"@type":"WebSite","@id":"https:\/\/futurenews24.com\/#website","url":"https:\/\/futurenews24.com\/","name":"Future News 24","description":"The Smart Hub for AI and Next-Gen Innovation","publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/futurenews24.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/futurenews24.com\/#organization","name":"Future News 24","url":"https:\/\/futurenews24.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/","url":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","contentUrl":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","width":250,"height":250,"caption":"Future News 24"},"image":{"@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83","name":"Future News 24","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","caption":"Future News 24"},"sameAs":["https:\/\/futurenews24.com"],"url":"https:\/\/futurenews24.com\/index.php\/author\/mridulpahuja20\/"}]}},"_links":{"self":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/3647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/comments?post=3647"}],"version-history":[{"count":1,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/3647\/revisions"}],"predecessor-version":[{"id":3648,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/3647\/revisions\/3648"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media\/3649"}],"wp:attachment":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media?parent=3647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/categories?post=3647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/tags?post=3647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}